<DOC>
	<DOCNO>NCT00302237</DOCNO>
	<brief_summary>The purpose registry : 1 ) To provide ongoing post-market surveillance mechanism document clinical outcome . 2 ) To provide additional information RX ACCULINK™ RX ACCUNET™ use safely wide range physician commercial use condition . 3 ) To evaluate adequacy Abbott Vascular 's physician training program .</brief_summary>
	<brief_title>CAPTURE 2 Post-Marketing Registry</brief_title>
	<detailed_description>CAPTURE 2 amendment CAPTURE study provide mechanism collection data RX ACCULINK RX ACCUNET Systems , use broad group physicians commercial use condition . The original CAPTURE study built-in feature limited ability collect on-going real world data restrict number site could participate ( 150 site ) limit enrollment site ( 40 patient per site ) . CAPTURE 2 restriction . CAPTURE 2 descriptive post-approval registry conduct approximately 400 clinical site United States open-ended enrollment . The purpose registry : 1 ) To provide ongoing post-market surveillance mechanism document clinical outcome . 2 ) To provide additional information RX ACCULINK Carotid Stent System RX ACCUNET Embolic Protection System ( EPS ) use safely wide range physician commercial use condition . 3 ) To evaluate adequacy Abbott Vascular 's physician training program . As previous CAPTURE study , data continue collect rare unanticipated event may occur . Patients CAPTURE 2 follow index procedure 30 day . During 30 day follow-up period , occurrence death , stroke , myocardial infarction ( MI ) , new neurologic event , device-related adverse event report Abbott Vascular .</detailed_description>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<criteria>1 . Informed Consent data collection . 2 . Intent use RX ACCULINK RX ACCUNET treat carotid artery disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>carotid , stenting , angioplasty</keyword>
</DOC>